Evidence map›Paper›PMID 37847431›Full record

ArticlePituitary2023

The impact of facility type and volume on treatment and overall survival in craniopharyngioma.

Benjamin F Bitner, Derek H Liu, Madeline M Nottoli, Sina J Torabi, Frank P K Hsu, Edward C Kuan

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Impact of stereotactic radiotherapy for craniopharyngioma: a large, academic hospital cohort.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Benjamin F BitnerDepartment of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA.
Derek H LiuDepartment of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA.
Madeline M NottoliDepartment of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA.
Sina J TorabiDepartment of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA.
Frank P K HsuDepartment of Neurological Surgery, University of California Irvine Medical Center, Orange, CA, USA.
Edward C KuanDepartment of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA. eckuan@uci.edu.
University of California, Irvine Medical Center · USNeurological Surgery · USPhoenix (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCraniopharyngiomas are uncommon benign sellar and parasellar tumors with high overall survival (OS) and recurrence rates. Treatment is often surgical but may include adjuvant therapies. The impact of adjuvant therapy and surgical approach have been evaluated, however, facility volume and type have not. The purpose of this study is to analyze the influence of facility volume and type on treatment modalities, extent of surgery and survival of craniopharyngioma.

methodsThe 2004-2016 National Cancer Database (NCDB) was queried for patients diagnosed with craniopharyngioma. Facilities were classified by type (academic vs. non-academic) and low-volume center (LVC) (Treating < 8 patients over the timeline) versus high-volume center (HVC), (Treating ≥ 8 patients over the timeline). Differences in treatment course, outcomes, and OS by facility type were assessed.

results3730 patients (51.3% female) with mean age 41.2 ± 22.0 were included with a 5-year estimated OS of 94.8% (94.0-95.5%). 2564 (68.7%) patients were treated at HVC, of which 2142 (83.5%) were treated at academic facilities. Patients treated at HVC's were more likely to undergo both surgery and radiation. Surgical approach at HVC was more likely to be endoscopic. Patients treated at HVC demonstrated significantly higher 5-year OS compared to patients treated at LVC (96% [95% CI 95.6-97.1% versus 91.2% [95% CI 89-92.7%] with lower risk of mortality (Hazard ratio [95% CI] = 0.69 [0.56-0.84]).

conclusionTreatment of craniopharyngioma at HVC compared to LVC is associated with improved OS, lower 30- and 90-day postoperative mortality risk, and more common use of both radiotherapy and endoscopic surgical approach.

Indexed as

CraniopharyngiomaPituitary NeoplasmsAdultCombined Modality TherapyDatabases, FactualFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesTreatment OutcomeYoung AdultCraniopharyngiomaEEAFacility volumeOutcomesOverall survival

Identifiers

PMID37847431
OpenAlexW4387692600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.